Delcath Systems, Inc. DCTH 深 沪
等待开盘 05-18 09:30:00 美东时间
11.07
-0.390
-3.40%
华盛通- 最 高11.32
- 今 开11.00
- 成交量 55.06万股
- 最 低 10.87
- 昨 收 11.46
- 总市值 3.82亿
- 52周最高 17.352
- 市盈率 静 163.76
- 换手率 1.60%
- 52周最低 8.12
- 委 比 -9.11%
- 总股本 3452.16万
- 历史最高 9368800000.00
- 量 比 0.92
- 振 幅 3.93%
- 历史最低 2.25
- 每 手 1
- 风险率 2.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Delcath Systems FY2026 Revenue expected to be more than $100.000M vs $104.070M Est
Delcath Systems (NASDAQ:DCTH) FY2026 Revenue expected to be more than $100.000M vs $104.070M Est
05-07 20:47
Delcath Systems' CHEMOSAT M-PHP Recognized As Recommended Liver-Directed Therapy For Metastatic Uveal Melanoma In 2026 ESMO–EURACAN Guidelines
Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced that its proprietary CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous
04-06 21:09
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
Delcath Systems shares are trading lower. The company reported Q4 financial results.
Delcath Systems shares are trading lower. The company reported Q4 financial res...
02-26 23:50
Delcath Systems FY2026 Total CHEMOSAT and HEPZATO KIT Revenue expected to be more than $100.000M vs $112.895M Est
Delcath Systems (NASDAQ:DCTH) FY2026 Total CHEMOSAT and HEPZATO KIT Revenue expected to be more than $100.000M vs $112.895M Est
02-26 22:18
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
HC Wainwright & Co. Reiterates Buy on Delcath Systems, Maintains $30 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:DCTH) with a Buy and maintains $30 price target.
01-10 01:30
Delcath Systems Publishes Phase 3 FOCUS Subgroup Analyses Showing Consistent Efficacy And Safety Of HEPZATO KIT In Unresectable Metastatic Uveal Melanoma In The Journal Of Cancer Research And Clinical Oncology
Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from
2025-12-31 21:03
Delcath Systems 10-Year Data From Retrospective Study On Patients With Liver-Dominant Metastatic Uveal Melanoma Shows Safety, Efficacy Of CHEMOSAT
Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a retrospective
2025-12-04 05:06
